Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India
MetadataShow full item record
Background: During the development of a vaccine, identification of the correlates of protection is of paramount importance for establishing an objective criterion for the protective performance of the vaccine. However, the ascertainment of correlates of immunity conferred by any vaccine is a difficult task. Methods: While conducting a phase three double-blind, cluster-randomized, placebo-controlled trial of a bivalent killed whole-cell oral cholera vaccine in Kolkata, we evaluated the immunogenicity of the vaccine in a subset of participants. Randomly chosen participants (recipients of vaccine or placebo) were invited to provide blood samples at baseline, 14 days after the second dose and one year after the first dose. At these time points, serum geometric mean titers (GMT) of vibriocidal antibodies and seroconversion rates for vaccine and placebo arms were calculated and compared across the age strata (1 to 5 years, 5 to 15 years and more than 15 years) as well as for all age groups. Results: Out of 137 subjects included in analysis, 69 were vaccinees and 68 received placebo. There were 5•7 and 5•8 geometric mean fold (GMF) rises in titers to Vibrio cholerae Inaba and Ogawa, respectively at 14 days after the second dose, with 57% and 61% of vaccinees showing a four-fold or greater titer rise, respectively. After one year, the titers to Inaba and Ogawa remained 1•7 and 2•8 fold higher, respectively, compared to baseline. Serum vibriocidal antibody response to V. cholerae O139 was much lower than that to Inaba or Ogawa. No significant differences in the GMF-rises were observed among the age groups. Conclusions: The reformulated oral cholera vaccine induced a statistically significant anti-O1 Inaba and O1 Ogawa vibriocidal antibody response 14 days after vaccination, which although declined after one year remained significantly higher than baseline. Despite this decline, the vaccine remained protective five years after vaccination. © 2014 Kanungo et al.
Showing items related by title, author, creator and subject.
Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of ageSaha, A.; Chowdhury, M.; Khanam, F.; Bhuiyan, M.; Chowdhury, F.; Khan, A.; Khan, I.; Clemens, J.; Ali, Mohammed; Cravioto, A.; Qadri, F. (2011)Background: Safety and immunogenicity study of an oral, killed, bivalent whole-cell, cholera vaccine, Shanchol was carried out in Bangladeshi participants. This study was conducted prior to initiating a feasibility study ...
Qadri, F.; Wierzba, T.; Ali, Mohammed; Chowdhury, F.; Khan, A.; Saha, A.; Khan, I.; Asaduzzaman, M.; Akter, A.; Khan, A.; Begum, Y.; Bhuiyan, T.; Khanam, F.; Chowdhury, M.; Islam, T.; Chowdhury, A.; Rahman, A.; Siddique, S.; You, Y.; Kim, D.; Siddik, A.; Saha, N.; Kabir, A.; Cravioto, A.; Desai, S.; Singh, A.; Clemens, J. (2016)Copyright © 2016 Massachusetts Medical Society. All rights reserved. Background: A single-dose regimen of the current killed oral cholera vaccines that have been prequalified by the World Health Organization would make ...
Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccinationVan Den Biggelaar, A.; Richmond, P.; Fuery, A.; Anderson, D.; Opa, C.; Saleu, G.; Lai, M.; Francis, J.; Alpers, Michael Philip; Pomat, W.; Lehmann, D. (2017)Trial design: In an earlier trial, Papua New Guinean (PNG) children at high risk of pneumococcal disease were randomized to receive 0 or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7), followed by a single dose ...